Darbepoetin alfa (Aranesp)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.[1][2][3][4]
Route: SC, IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

History of changes in PMDA indication

  • 2014-12-18: New additional indication and a new dosage for the treatment of anemia due to myelodysplastic syndrome.

Also known as

  • Brand names: Actorise, Aranesp, Bionesp, Cresp, Darbetin, Darbex, Derise, Kabidarba, Nesp, Nespo


  1. 1.0 1.1 1.2 Darbepoetin alfa (Aranesp) package insert
  2. Darbepoetin alfa (Aranesp) package insert (locally hosted backup)
  3. Aranesp manufacturer's website
  4. As of 4/14/2017, use of this medication in patients with oncologic diagnoses no longer requires enrollment in the ESA APPRISE Risk Evaluation and Mitigation Strategy (REMS) Program
  5. Darbepoetin alfa (Aranesp) patient drug information (Chemocare)
  6. Darbepoetin alfa (Aranesp) patient drug information (UpToDate)